KPRX (Kiora Pharmaceuticals) Change In Working Capital : $2.74 Mil (TTM As of Mar. 2025)

View and export this data going back to 2015. Start your Free Trial

What is Kiora Pharmaceuticals Change In Working Capital?

Kiora Pharmaceuticals's change in working capital for the quarter that ended in Mar. 2025 was $-0.93 Mil.

Kiora Pharmaceuticals's change in working capital for the fiscal year that ended in Dec. 2024 was $3.67 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Kiora Pharmaceuticals Change In Working Capital Historical Data

The historical data trend for Kiora Pharmaceuticals's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiora Pharmaceuticals Change In Working Capital Chart

Kiora Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Working Capital

Get a 7-Day Free Trial

-0.32

-1.04

0.67

-1.82

3.67

Kiora Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Working Capital	Get a 7-Day Free Trial															-0.01	-1.73	3.30	2.10	-0.93

Kiora Pharmaceuticals Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.74 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Kiora Pharmaceuticals Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Kiora Pharmaceuticals's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Kiora Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiora Pharmaceuticals Inc (NAS:KPRX) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

332 Encinitas Boulevard, Suite 102, Encinitas, CA, USA, 92024

Website

https://www.kiorapharma.com

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Executives

Carmine N. Stengone	director	10578 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Aron Shapiro	director	C/O EYEGATE PHARMACEUTICALS INC., 271 WAVERLY OAKS RD., STE 108, WALTHAM MA 02452
Praveen Tyle	director	ONE BAUSCH & LOMB PLACE, ROCHESTER NY 14604
Melissa Tosca	officer: EVP of Finance	C/O KIORA PHARMACEUTICALS, INC., 1371 EAST 2100 SOUTH, SUITE 200, SALT LAKE CITY UT 84105
Eric Joseph Daniels	officer: Chief Development Officer	C/O EYEGATE PHARMACEUTICALS INC., 271 WAVERLY OAKS RD., STE 108, WALTHAM MA 02452
Brian M. Strem	director, officer: President and CEO	C/O EYEGATE PHARMACEUTICALS INC., 271 WAVERLY OAKS RD., STE 108, WALTHAM MA 02452
Erin Parsons	director	97 WILLISTON RD, BROOKLINE MA 02445
Susan L. Drexler	officer: Interim CFO	630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
David Hollander	director	C/O AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Armistice Capital Master Fund Ltd.	director, 10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc	director, 10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd	director, 10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Kenneth L Gayron	director	75 NETWORK DRIVE, BURLINGTON MA 34212
Franz Obermayr	officer: Acting CEO	C/O EYEGATE PHARMACEUTICALS, INC., 271 WAVERLEY OAKS ROAD, SUITE 108, WALTHAM MA 02452
Thomas Hancock	director	C/O BURNS & LEVINSON LLP, 125 SUMMER STREET, BOSTON MA 02110